{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:07:36Z","timestamp":1794028056834,"version":"4.8.0"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Noonan syndrome is characterized by multiple phenotypic features, including growth retardation, which represents the main cause of consultation to the clinician. Longitudinal growth during childhood and adolescence depends on several factors, among them an intact somatotrophic axis, which is characterized by an adequate growth hormone (GH) secretion by the pituitary, subsequent binding to its receptor, proper function of the post-receptor signaling pathway for this hormone (JAK-STAT5b and RAS\/MAPK), and ultimately by the production of its main effector, insulin like growth factor 1 (IGF-1). Several studies regarding the function of the somatotrophic axis in patients with Noonan syndrome and data from murine models, suggest that partial GH insensitivity at a post-receptor level, as well as possible derangements in the RAS\/MAPK pathway, are the most likely causes for the growth failure in these patients. Treatment with recombinant human growth hormone (rhGH) has been used extensively to promote linear growth in these patients. Numerous treatment protocols have been employed so far, but the published studies are quite heterogeneous regarding patient selection, length of treatment, and dose of rhGH utilized, so the true benefit of GH therapy is somewhat difficult to establish. This review will discuss the possible etiologies for the growth delay, as well as the outcomes following rhGH treatment in patients with Noonan syndrome.<\/jats:p>","DOI":"10.3389\/fendo.2021.691240","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T06:18:12Z","timestamp":1622787492000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Etiology and Treatment of Growth Delay in Noonan Syndrome"],"prefix":"10.3389","volume":"12","author":[{"given":"Fernando","family":"Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena","family":"Gaete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Cassorla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/jmg.24.1.9","article-title":"Noonan Syndrome.","volume":"24","author":"Allanson","year":"1987","journal-title":"J Med Genet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.67.2.178","article-title":"A Clinical Study of Noonan Syndrome","volume":"67","author":"Sharland","year":"1992","journal-title":"Arch Dis Child"},{"key":"B3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/ajmg.1320210312","article-title":"Noonan Syndrome: A Review","volume":"21","author":"Mendez","year":"1985","journal-title":"Am J Med Genet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2006.104547","article-title":"The Natural History of Noonan Syndrome: A Long-Term Follow-Up Study","volume":"92","author":"Shaw","year":"2007","journal-title":"Arch Dis Child"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-2-4","article-title":"Noonan Syndrome","volume":"2","author":"van der Burgt","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61023-X","article-title":"Noonan Syndrome","volume":"381","author":"Roberts","year":"2013","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2015.114","article-title":"Recent Advances in Rasopathies","volume":"61","author":"Aoki","year":"2016","journal-title":"J Hum Genet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-020-00743-3","article-title":"The Clinical Significance of A2ML1 Variants in Noonan Syndrome has to be Reconsidered","volume":"29","author":"Brinkmann","year":"2021","journal-title":"Eur J Hum Genet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40142-016-0100-7","article-title":"Expansion of the Rasopathies","volume":"4","author":"Tidyman","year":"2016","journal-title":"Curr Genet Med Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ18-0564","article-title":"Genotype-Phenotype Correlation Analysis in Japanese Patients With Noonan Syndrome","volume":"66","author":"Shoji","year":"2019","journal-title":"Endocr J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-021-2092-y","article-title":"Mutation and Phenotypic Spectrum of Patients With Rasopathies","volume":"58","author":"Lallar","year":"2021","journal-title":"Indian Pediatr"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0922","article-title":"Growth Patterns of Patients With Noonan Syndrome: Correlation With Age and Genotype","volume":"174","author":"Cessans","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.35519","article-title":"Growth Standards of Patients With Noonan and Noonan-like Syndromes With Mutations in the RAS\/MAPK Pathway","author":"Malaquias","year":"2012","journal-title":"Am J Med Genet A"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/pd.2804","article-title":"Prenatal Features of Noonan Syndrome: Prevalence and Prognostic Value","volume":"31","author":"Baldassarre","year":"2011","journal-title":"Prenat Diagn"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.38649","article-title":"First-Year Growth in Children With Noonan Syndrome: Associated With Feeding Problems","volume":"176","author":"Croonen","year":"2018","journal-title":"Am J Med Genet A"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2094","article-title":"Growth Response, Near-Adult Height, and Patterns of Growth and Puberty in Patients With Noonan Syndrome Treated With Growth Hormone","volume":"94","author":"Romano","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ajmg.a.20502","article-title":"Adult Height in Noonan Syndrome","author":"Noonan","year":"2003","journal-title":"Am J Med Genet A"},{"key":"B18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/MED.0000000000000380","article-title":"Noonan Syndrome: An Update on Growth and Development","volume":"25","author":"Yart","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(96)70005-7","article-title":"Growth Hormone Treatment in Noonan Syndrome: The National Cooperative Growth Study Experience","volume":"128","author":"Romano","year":"1996","journal-title":"J Pediatr"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.81.6.8964866","article-title":"The Short-Term Effects of Growth Hormone Therapy on Height Velocity and Cardiac Ventricular Wall Thickness in Children With Noonan\u2019s Syndrome","volume":"81","author":"Cotterill","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1159\/000145016","article-title":"Abnormal Growth in Noonan Syndrome: Genetic and Endocrine Features and Optimal Treatment","volume":"70","author":"Padidela","year":"2008","journal-title":"Horm Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.31.908","article-title":"Noonan Syndrome Presenting Growth Hormone Neurosecretory Dysfunction","volume":"31","author":"Tanaka","year":"1992","journal-title":"Intern Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0995","article-title":"PTPN11 Mutations are Associated With Mild Growth Hormone Resistance in Individuals With Noonan Syndrome","volume":"90","author":"Binder","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2001.01188.x","article-title":"Growth Hormone (GH) Secretion in Children With Noonan Syndrome: Frequently Abnormal Without Consequences for Growth or Response to GH Treatment","volume":"54","author":"Noordam","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0983","article-title":"Noonan Syndrome: Relationships Between Genotype, Growth, and Growth Factors","volume":"9","author":"Limal","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/BF03401289","article-title":"IGF-I Generation Test in Prepubertal Children With Noonan Syndrome Due to Mutations in the","volume":"12","author":"Bertelloni","year":"2013","journal-title":"PTPN11 gene Hormones (Athens)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/978-1-4939-6424-6_28","article-title":"Modeling RASopathies With Genetically Modified Mouse Models","volume":"1487","author":"Hern\u00e1ndez-Porras","year":"2017","journal-title":"Methods Mol Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nm1084","article-title":"Mouse Model of Noonan Syndrome Reveals Cell Type- and Gene Dosage-Dependent Effects of Ptpn11 Mutation","volume":"10","author":"Araki","year":"2004","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1119803109","article-title":"Noonan Syndrome-Causing SHP2 Mutants Inhibit Insulin-Like Growth Factor 1 Release Via Growth Hormone-Induced ERK Hyperactivation, Which Contributes to Short Stature","volume":"109","author":"De Rocca Serra-N\u00e9d\u00e9lec","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddy133","article-title":"Noonan Syndrome-Causing SHP2 Mutants Impair ERK-dependent Chondrocyte Differentiation During Endochondral Bone Growth","volume":"27","author":"Tajan","year":"2018","journal-title":"Hum Mol Genet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1172\/JCI43910","article-title":"Activation of Multiple Signaling Pathways Causes Developmental Defects in Mice With a Noonan Syndrome\u2013Associated","volume":"120","author":"Chen","year":"2010","journal-title":"Sos1 mutation J Clin Invest"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1418126111","article-title":"K-RasV14I Recapitulates Noonan Syndrome in Mice","volume":"111","author":"Hern\u00e1ndez-Porras","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ebiom.2019.03.014","article-title":"New Noonan Syndrome Model Mice With RIT1 Mutation Exhibit Cardiac Hypertrophy and Susceptibility to \u03b2-Adrenergic Stimulation-Induced Cardiac Fibrosis","volume":"42","author":"Takahara","year":"2019","journal-title":"EBioMedicine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/JCI44929","article-title":"Mek-ERK Pathway Modulation Ameliorates Disease Phenotypes in a Mouse Model of Noonan Syndrome Associated With the Raf1L613V Mutation","volume":"121","author":"Wu","year":"2011","journal-title":"J Clin Invest"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.006130","article-title":"Development of Severe Skeletal Defects in Induced SHP-2-deficient Adult Mice: A Model of Skeletal Malformation in Humans With SHP-2 Mutations","volume":"4","author":"Bauler","year":"2011","journal-title":"Dis Model Mech"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e1004364","DOI":"10.1371\/journal.pgen.1004364","article-title":"SHP2 Regulates Chondrocyte Terminal Differentiation, Growth Plate Architecture and Skeletal Cell Fates","volume":"10","author":"Bowen","year":"2014","journal-title":"PloS Genet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1210\/edrv.21.1.0387","article-title":"The Molecular and Genetic Basis of Fibroblast Growth Factor Receptor 3 Disorders: The Achondroplasia Family of Skeletal Dysplasias, Muenke Craniosynostosis, and Crouzon Syndrome With Acanthosis Nigricans","volume":"21","author":"Vajo","year":"2000","journal-title":"Endocr Rev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2012.10.014","article-title":"Evaluation of the Therapeutic Potential of a CNP Analog in a Fgfr3 Mouse Model Recapitulating Achondroplasia","volume":"91","author":"Lorget","year":"2012","journal-title":"Am J Hum Genet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M301362200","article-title":"Acute Control of Insulin-Like Growth Factor-I Gene Transcription by Growth Hormone Through Stat5b","volume":"278","author":"Woelfle","year":"2003","journal-title":"J Biol Chem"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1210\/mend.14.9.0513","article-title":"Mutation of the SHP-2 Binding Site in Growth Hormone (GH) Receptor Prolongs GH-promoted Tyrosyl Phosphorylation of GH Receptor, JAK2, and STAT5B","volume":"14","author":"Stofega","year":"2000","journal-title":"Mol Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1737","article-title":"An Agonist-Induced Conformational Change in the Growth Hormone Receptor Determines the Choice of Signalling Pathway","volume":"10","author":"Rowlinson","year":"2008","journal-title":"Nat Cell Biol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M201385200","article-title":"Identification of a JAK2-independent Pathway Regulating Growth Hormone (GH)-Stimulated p44\/42 Mitogen-Activated Protein Kinase Activity. GH Activation of Ral and Phospholipase D is Src-Dependent","volume":"277","author":"Zhu","year":"2002","journal-title":"J Biol Chem"},{"key":"B43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3266\/pre2020.Jul.584","article-title":"Tratamiento Con Hormona De Crecimiento En El Sindrome De Noonan: Revisi\u00f3n De La Bibliograf\u00eda Y Recomendaciones Del Tratamiento","volume":"11","author":"Carcavilla","year":"2020","journal-title":"Rev Esp Endocrinol Pediatr"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1159\/000371635","article-title":"The Impact of Growth Hormone Therapy on Adult Height in Noonan Syndrome: A Systematic Review","volume":"83","author":"Giacomozzi","year":"2015","journal-title":"Horm Res Paediatr"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/adc.84.5.440","article-title":"Short Stature in Noonan Syndrome: Response to Growth Hormone Therapy","volume":"84","author":"Kirk","year":"2001","journal-title":"Arch Child"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1997.tb15175.x","article-title":"Growth Hormone Therapy in Pre-Pubertal Children With Noonan Syndrome: First Year Growth Response and Comparison With Turner Syndrome","volume":"86","author":"de Schepper","year":"1997","journal-title":"Acta Paediatr"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1991.tb11880.x","article-title":"Noonan\u2019s Syndrome: Abnormalities of the Growth Hormone\/IGF-I Axis and the Response to Treatment With Human Biosynthetic Growth Hormone","volume":"80","author":"Ahmed","year":"1991","journal-title":"Acta Paediatr Scand"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4274\/jcrpe.3013","article-title":"The Growth Characteristics of Patients With Noonan Syndrome: Results of Three Years of Growth Hormone Treatment: A Nationwide Multicenter Study","volume":"8","author":"\u015eklar","year":"2016","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.5.7468","article-title":"Growth Hormone Therapy and Growth in Children With Noonan\u2019s Syndrome: Results of 3 Years\u2019 Follow-Up","volume":"86","author":"MacFarlane","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13633-015-0015-1","article-title":"Noonan Syndrome and Turner Syndrome Patients Respond Similarly to 4 Years\u2019 Growth-Hormone Therapy: Longitudinal Analysis of Growth-Hormone-Na\u00efve Patients Enrolled in the NordiNet\u00ae International Outcome Study and the ANSWER Program","volume":"2015","author":"Lee","year":"2015","journal-title":"Int J Pediatr Endocrinol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ19-0371","article-title":"Long-Term Efficacy and Safety of Two Doses of Norditropin\u00ae (Somatropin) in Noonan Syndrome: A 4-Year Randomized, Double-Blind, Multicenter Trial in Japanese Patients","volume":"67","author":"Horikawa","year":"2020","journal-title":"Endocr J"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1159\/000184618","article-title":"Growth Hormone Treatment in Noonan Syndrome: Report of Four Cases Who Reached Final Height","volume":"44","author":"Municchi","year":"1995","journal-title":"Horm Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2005.tb02081.x","article-title":"Improved Final Height With Long-Term Growth Hormone Treatment in Noonan Syndrome","volume":"94","author":"Osio","year":"2005","journal-title":"Acta Paediatr"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1515\/jpem.2008.21.3.267","article-title":"Response to Growth Hormone Treatment and Final Height in Noonan Syndrome in a Large Cohort of Patients in the KIGS Database","volume":"21","author":"Raaijmakers","year":"2008","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0413","article-title":"Long-Term GH Treatment Improves Adult Height in Children With Noonan Syndrome With and Without Mutations in Protein Tyrosine Phosphatase, non-Receptor Type 11","volume":"159","author":"Noordam","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000498859","article-title":"Treatment With Growth Hormone in Noonan Syndrome Observed During 25 Years of KIGS: Near Adult Height and Outcome Prediction","volume":"91","author":"Ranke","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1159\/000243779","article-title":"Growth Hormone Therapy in Noonan Syndrome: Review of Final Height Data","volume":"72","author":"Dahlgren","year":"2009","journal-title":"Horm Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2012.02.043","article-title":"Health and Quality of Life in Adults With Noonan Syndrome","volume":"161","author":"Binder","year":"2012","journal-title":"J Pediatr"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.37260","article-title":"Response to Long-Term Growth Hormone Therapy in Patients Affected by RASopathies and Growth Hormone Deficiency: Patterns of Growth, Puberty and Final Height Data","author":"Tamburrino","year":"2015","journal-title":"Am J Med Genet A"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1159\/000500264","article-title":"Impact of Growth Hormone Therapy on Adult Height in Patients With PTPN11 Mutations Related to Noonan Syndrome","volume":"91","author":"Malaquias","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ17-0313","article-title":"Efficacy and Safety of Two Doses of Norditropin\u00ae (Somatropin) in Short Stature Due to Noonan Syndrome: A 2-Year Randomized, Double-Blind, Multi- Center Trial in Japanese Patients","volume":"65","author":"Ozono","year":"2018","journal-title":"Endocr J"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(99)70089-2","article-title":"Patterns of Cognitive Functioning in School-Aged Children With Noonan Syndrome Associated With Variability in Phenotypic Expression","volume":"135","author":"van der Burgt","year":"1999","journal-title":"J Pediatr"},{"key":"B63","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13052-015-0183-x","article-title":"Five-Year Response to Growth Hormone in Children With Noonan Syndrome and Growth Hormone Deficiency","volume":"41","author":"Zavras","year":"2015","journal-title":"Ital J Pediatr"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e205199","DOI":"10.1001\/jamapediatrics.2020.5199","article-title":"Association of Childhood Growth Hormone Treatment With Long-Term Cardiovascular Morbidity","volume":"175","author":"Tidblad","year":"2021","journal-title":"JAMA Pediatr"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2046","article-title":"Cancer Risks in Patients Treated With Growth Hormone in Childhood: The Saghe European Cohort Study","volume":"102","author":"Swerdlow","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30163-7","article-title":"Long-Term Mortality After Childhood Growth Hormone Treatment: The SAGhE Cohort Study","volume":"8","author":"S\u00e4vendahl","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1159\/000048101","article-title":"Effects of Growth Hormone Treatment on Left Ventricular Dimensions in Children With Noonan\u2019s Syndrome","volume":"56","author":"Noordam","year":"2001","journal-title":"Horm Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.75","article-title":"Cancer Spectrum and Frequency Among Children With Noonan, Costello, and Cardio-Facio-Cutaneous Syndromes","volume":"112","author":"Kratz","year":"2015","journal-title":"Br J Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0631","article-title":"Recommendations for Cancer Surveillance in Individuals With RASopathies and Other Rare Genetic Conditions With Increased Cancer Risk","volume":"23","author":"Villani","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"61.e1","DOI":"10.1016\/j.anpedi.2020.04.008","article-title":"Noonan Syndrome: Genetic and Clinical Update and Treatment Options","volume":"93","author":"Carcavilla","year":"2020","journal-title":"Pediatr (Barc)"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.691240\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T06:18:14Z","timestamp":1622787494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.691240\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,4]]},"references-count":70,"alternative-id":["10.3389\/fendo.2021.691240"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.691240","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,4]]},"article-number":"691240"}}